DeepOncology AI

Company Overview

Snapshot

Founded in February 2018 by Shlomo Kashani, DeepOncology AI operated with 1–10 employees. The company ceased operations in October 2021.

Business overview

DeepOncology AI developed technology for the visual detection of liver cancer, leveraging deep learning techniques in radiology and oncology. The company focused on addressing the need for automated analysis tools to screen for liver metastases using 3D imaging, integrating artificial intelligence and computer vision to facilitate clinical cancer research and diagnosis. Its DeepOn device aimed to offer precise tumor characterization and early diagnosis and treatment, serving the healthcare sector, particularly healthcare providers, hospitals, and clinics.

Company Intelligence Q&A

What is DeepOncology AI's primary focus?

DeepOncology AI focuses on utilizing deep learning, artificial intelligence, and computer vision to develop technology for the visual detection of liver cancer, aiding clinical cancer research and diagnosis.

When was DeepOncology AI founded?

DeepOncology AI was founded in February 2018.

Who founded DeepOncology AI?

DeepOncology AI was founded by Shlomo Kashani, who also served as its Chief Data Scientist.

What was the operational status of DeepOncology AI?

DeepOncology AI ceased to operate in October 2021.

What technology did DeepOncology AI develop?

DeepOncology AI developed the DeepOn device, which uses artificial intelligence and computer vision for the visual detection of liver cancer, aiming for precise tumor characterization and early diagnosis.